

PITAVASTATIN TO PREVENT CVS IN HIV

OBJECTIVE: to assess efficacy and safety of pitavastatin for CVS prevention amongst PLHIV

INTERVENTION: 7769 PLHIV (stable) aged 40-75 (3888 on 4mg pitavastatin vs 3881 on placebo)

RESULT: In PLHIV receiving stable cART with low-moderate CVS risk, daily pitavastatin resulted in significantly lower risk of CVS than placebo over nearly 5 years of follow-up.

PHASE 3, MULTINATIONAL,
RANDOMISED, PLACEBO-CONTROLLED
TRIAL
REPRIEVE

